1H-Pyrazole-1-carboxamide, 5-[5-bromo-1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-1H-indol-3-yl]-4,5-dihydro-3-[4-(trifluoromethyl)phenyl]-, (5S)- manufacturers
- JAK2/STAT3-IN-1
-
- $293.00
-
2026-08-19
- CAS:2485758-50-5
- Purity: 97.35%
- Supply Ability: 10g
|
| | 1H-Pyrazole-1-carboxamide, 5-[5-bromo-1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-1H-indol-3-yl]-4,5-dihydro-3-[4-(trifluoromethyl)phenyl]-, (5S)- Basic information |
| | 1H-Pyrazole-1-carboxamide, 5-[5-bromo-1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-1H-indol-3-yl]-4,5-dihydro-3-[4-(trifluoromethyl)phenyl]-, (5S)- Chemical Properties |
| Boiling point | 776.2±70.0 °C(Predicted) | | density | 1.44±0.1 g/cm3(Predicted) | | pka | 15+-.0.60(Predicted) |
| | 1H-Pyrazole-1-carboxamide, 5-[5-bromo-1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-1H-indol-3-yl]-4,5-dihydro-3-[4-(trifluoromethyl)phenyl]-, (5S)- Usage And Synthesis |
| Uses | JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC50 of 3.04 μM. JAK2/STAT3-IN-1 shows anti-tumor activity[1]. | | References | [1] Song D, et al. Discovery of bazedoxifene analogues targeting glycoprotein 130. Eur J Med Chem. 2020 Aug 1;199:112375. DOI:10.1016/j.ejmech.2020.112375 |
| | 1H-Pyrazole-1-carboxamide, 5-[5-bromo-1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-1H-indol-3-yl]-4,5-dihydro-3-[4-(trifluoromethyl)phenyl]-, (5S)- Preparation Products And Raw materials |
|